

CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER: 020287/S010

MEDICAL REVIEW(S)

Oliver

MAY 25 1999

DIVISION OF GASTROINTESTINAL AND COAGULATION DRUG PRODUCTS

MEDICAL OFFICER'S REVIEW

NDA: 20-287/S-010

Drug name: Fragmin

Generic name: Dalteparin Sodium

Other names: FR-860, Heparin fragment Kabi-2165, Kabi 2165, Tedelparin

Chemical name: Nitrous acid degradation product of porcine intestinal mucosa. Majority of components have a 2-O-sulpho-alpha-L- idophyanosuronic reducing end of their chain

Structure:

Sponsor: Pharmacia & Upjohn, Kalamazoo, Michigan

Pharmacologic Category: Anticoagulant and Antithrombotic
Low Molecular Weight Heparin

Proposed Indications: Unstable angina and non-Q-wave myocardial infarction

Dosage Form(s) and Route(s) of Administration: 120 IU/kg (Max 10,000U/dose) s.c. every 12 hours
In conjunction with aspirin

Important Related Drugs: Enoxaparin (Lovenox®)
Ardeparin (Normiflo®)
Danaparoid (Orgaran®)

Related reviews: NDA 20-287, NDA 20-287/S-008, IND [REDACTED]

Date of Submission: May 29, 1998

Date received by HFD-180: June 1, 1998

Date of Review: February 11, 1999

Medical Reviewer: John William Schmeling, M.D., Ph.D.

TABLE OF CONTENTS

TABLE OF CONTENTS	2
LIST OF TABLES	6
LIST OF FIGURES	7
ACRONYMS and ABBREVIATIONS	8
1. MATERIAL UTILIZED IN REVIEW	9
1.1 Materials from NDA/IND	9
1.2 Related Review, Consults	9
2. BACKGROUND	9
2.1 Indication	9
2.2 Rationale	9
2.2.1 Background for Treatment of Unstable Coronary Artery Disease	9
2.2.1.1 RISC trial	9
2.2.1.2 Thérroux et. al., the Canadian study	10
2.2.2 Rationale for using Fragmin® to treat unstable coronary artery syndromes	11
2.2.3 Rationale for Fragmin® dosage, acute phase and chronic phase	11
2.2.3.1 Acute phase	11
2.2.3.2 Chronic phase	12
2.3 Administrative History	12
2.4 Foreign experience	15
2.5 Current FDA approved use in the United States	15
2.5.1 Abdominal Surgery	15
2.5.2 Hip Replacement Surgery	15
3. REVIEW OF INDIVIDUAL STUDIES	16
3.1 Overview of studies submitted	16
3.1.1 FRISC	16
3.1.2 FRIC	16
3.1.3 FRISC II	17
3.1.4 FRAMI	17
3.1.5 Other studies	17
3.2 Pivotal studies	18
3.2.1 FRISC	18
3.2.1.1 Introduction	18
3.2.1.2 FRISC study summary	22
3.2.1.3 General study outline	29
3.2.1.4 Objective	29
3.2.1.5 Patient population	30
3.2.1.6 Inclusion criteria	30
3.2.1.7 Demographics and other baseline characteristics	30
3.2.1.7.1 Demographics	30
3.2.1.8 Aspirin use	30
3.2.1.9 Study treatments	32
3.2.1.10 Withdrawals	32

3.2.1.11 Efficacy results	36
3.2.1.11.1 Primary endpoint	36
3.2.1.11.1.1 Analysis of ITT group with all data points available	37
3.2.1.11.1.2 Worst case scenario	38
3.2.1.11.2 Primary endpoint components	39
3.2.1.11.3 Secondary endpoints	40
3.2.1.11.4 Variability among centers	41
3.2.1.11.5 Aspirin	41
3.2.1.12 Safety summary	42
3.2.1.12.1 Sponsor-specified safety endpoints	42
3.2.1.12.2 Deaths	43
3.2.1.12.3 Serious adverse events	46
3.2.1.12.3.1 Serious adverse events in Fragmin 120 IU/kg vs. placebo group	46
3.2.1.12.4 Adverse events leading to withdrawal from treatment in the Fragmin 120 IU/kg and placebo groups.	48
3.2.1.12.5 Conclusion	51
3.2.2 FRIC	52
3.2.2.1 Introduction	52
3.2.2.2 FRIC study summary	52
3.2.2.3 General study outline	60
3.2.2.4 Objectives	60
3.2.2.5 Patient population	61
3.2.2.6 Inclusion criteria	61
3.2.2.7 Demographics and baseline characteristics	61
3.2.2.8 Aspirin use	62
3.2.2.9 Withdrawals	63
3.2.2.9.1 Primary reason for withdrawal, Phase I and Phase II	63
3.2.2.9.2 All reasons for withdrawal, Phase I and Phase II	64
3.2.2.9.3 Withdrawal due to patient request ITT group, Phase I.	64
3.2.2.9.4 Withdrawal due to patient request in ITT group, Phase II	65
3.2.2.9.5 Withdrawal due to other reasons in Phase I	65
3.2.2.10 Efficacy results	66
3.2.2.10.1 Primary endpoint	66
3.2.2.10.2 Secondary endpoints	66
3.2.2.10.3 Phase I	66
3.2.2.10.4 Phase II	67
3.2.2.10.5 Variability among centers	67
3.2.2.11 FRIC safety summary	67
3.2.2.11.1 Sponsor-defined endpoints	67
3.2.2.11.2 Deaths	68
3.2.2.11.3 Serious adverse events during treatment phase	69
3.2.2.11.4 Adverse events, serious and non serious combined during treatment period	72
3.2.2.11.5 Adverse events, serious and non serious, during follow-up phase	75
3.2.2.12 Conclusion	76
4. REVIEW OF SAFETY (FRISC and FRIC combined)	77
4.1 Overall exposure	77
4.2 Deaths	77

4.2.1 Overall Number of deaths	77
4.2.2 Incidence and cause of death during or after acute treatment	78
4.2.3 Incidence and cause of death during or after chronic treatment	79
4.3 Serious adverse events	79
4.3.1 Sponsor-defined safety endpoints	79
4.3.1.1 Sponsor-defined safety endpoints during acute phase	79
4.3.1.2 Sponsor-defined safety endpoints during the chronic phase	80
4.3.1.3 Incidence of serious complications	81
4.3.1.3.1 Incidence of serious complications during the acute phases	81
4.3.1.4 Incidence of serious complications during the chronic phases	82
4.3.2 Types of adverse events resulting in treatment discontinuation during the acute treatment phase	83
4.3.3 Types of adverse events resulting in treatment discontinuation during the chronic phase	84
4.4 Laboratory evaluations	85
4.4.1 Hemoglobin	85
4.4.2 Platelets	86
4.5 Summary of Safety events	87
5. OVERVIEW OF EFFICACY (FRISC and FRIC combined)	87
5.1 Comparison of FRIC and FRISC	87
5.1.1 Primary endpoints	87
5.1.2 Treatment sequence	88
5.1.3 Aspirin	88
5.1.4 Age range	88
5.2 Efficacy results	88
5.2.1 FRISC	88
5.2.2 FRIC	89
6. DEFINITION OF UNSTABLE ANGINA	89
6.1.1 Use of the term unstable angina on the label	89
6.1.2 Sponsor's definition of unstable angina in the protocol	89
6.1.3 Braunwald's classification of unstable angina	90
6.1.4 Definition of unstable angina in common use	91
6.1.5 Conclusion	91
7. LABELING REVIEW	92
7.1 Proposed Labeling	92
7.2 Review of labeling	94
8. CONCLUSION	94
8.1 Efficacy	94
8.2 Safety	95
9. RECOMMENDATIONS	96
9.1 Approvable	96
10. APPENDICES	97
10.1 Definition of Unstable Coronary artery disease (FRISC)	97
10.2 Definition of myocardial infarction (FRISC 8/3/54-56)	98
10.3 Indications for coronary artery angiography (FRISC)	101
10.4 Indications for coronary artery angiography (FRIC)	103
10.5 Exercise test protocol (FRISC 8/3/50- 52)	104

NDA: 20-287/S-10

Page 5

<i>10.6 Indications for revascularization (FRISC)</i>	107
<i>10.7 Dosing ranges</i>	107
<i>10.8 Death and/or MI by center</i>	109
<i>10.9 FRIC treatment protocol</i>	111
<i>10.10 Definitions of death, MI, recurrent angina, revascularization, and ischemia during the exercise test in FRIC.</i>	112
<i>10.11 FRIC patients enrolled but not in ITT group</i>	114
11. REFERENCES	115

APPEARS THIS WAY ON ORIGINAL

LIST OF TABLES

Table 1:	The studies that the sponsor cites to support their dosing regimens	13
Table 2:	Summary of studies included in application	19
Table 3:	Study Summary: FRISC trial TRN: 91-115: Low molecular weight heparin, Fragmin®, in treatment of unstable coronary artery disease	22
Table 4:	Aspirin use	31
Table 5:	All reasons for treatment withdrawal for 120 IU/kg/12h	33
Table 6:	Primary reason for treatment withdrawal per phase for 120 IU/kg/12h	33
Table 7:	Comment's (coded) given for withdrawal from treatment due to patient's request as primary reason. For patient group 120IU/kg/12h	35
Table 8:	Comment's (coded) given for withdrawal from treatment due to other reasons as primary reason. (120 IU/kg/12h)	36
Table 9:	Death and/or MI by day 6 by treatment (sponsors analysis of 120 IU/kg vs. placebo)	37
Table 10:	Death and/or MI by day 6 by treatment (using all available data points) for the primary endpoint	38
Table 11:	Death and/or MI through day six: worst case scenario for the 120 IU Fragmin group	38
Table 12:	Death and/or MI through day six: worst case scenario for the 120 IU and 150 IU Fragmin groups combined	39
Table 13:	Primary endpoint broken down by components	40
Table 14:	Safety results: Phase I and II, Fragmin 150 IU/kg or placebo	42
Table 15:	Safety results: Phase I and II, Fragmin 120 IU/kg	43
Table 16:	Death, reason by endpoint committee	44
Table 17:	Death by study phase: Fragmin 150 IU/kg or Placebo	44
Table 18:	Death, reason by endpoint committee	45
Table 19:	Death by study phase, Fragmin 150 IU/kg or placebo	46
Table 20:	Death by study phase, Fragmin 120 IU/kg or placebo	46
Table 21:	Incidence of serious adverse events by phase and preferred terms: Fragmin 120 IU/kg or placebo	47
Table 22:	49	47
Table 23:	Study summary: FRIC trial CTN: 91-128 Low molecular weight heparin, Fragmin, in the treatment of unstable coronary artery disease	52
Table 24:	ASA use at admission, ITT group Phase I and Phase II	62
Table 25:	Use of ASA, prior to the start of study treatment, ITT group in Phase I and Phase II	62
Table 26:	Primary reason for treatment withdrawal, ITT group Phase I	63
Table 27:	Primary reason for treatment withdrawal, ITT group in Phase II	64
Table 28:	Reason for withdrawal due to patients request ITT group in Phase I	65
Table 29:	Reason for withdrawal due to patients request in ITT group, in Phase II	65
Table 30:	Reason for withdrawal due to other reason in ITT group, Phase I	66
Table 31:	Safety results: Phase I and II	68
Table 32:	Death reason assessed by investigator by study phase	68
Table 33:	Incidence of serious adverse events during Phase I and Phase II by preferred term	70
Table 34:	Incidence of adverse events, by preferred term and study phase	73
Table 35:	Adverse events, serous and non serious, during follow-up (reported in 2 or more patients)	76
Table 36:	Overall exposure to Fragmin in FRISC and FRIC studies	77
Table 37:	Overall Number of deaths in FRISC and FRIC	78
Table 38:	Incidence and cause of death during or after acute treatment in FRISC and FRIC trials	78
Table 39:	Incidence and cause of death during or after chronic treatment in FRISC and FRIC trials	79
Table 40:	Summary of serious events during the acute phase of FRISC and FRIC trials	80
Table 41:	Summary of sponsor-defined safety endpoints during the chronic phase of FRISC and FRIC trials	81
Table 42:	Incidence of serious complications during acute phase of FRISC and FRIC trials by treatment	82
Table 43:	Incidence of serious complications during chronic phase of FRISC and FRIC trials by treatment	83
Table 44:	Types of adverse events resulting in treatment discontinuation during the acute treatment phase	84
Table 45:	Types of adverse events resulting in treatment discontinuation during the chronic phase	85
Table 46:	Hemoglobin (g/L): mean and standard deviation over time by treatment and sex	86
Table 47:	Hemoglobin values of less than 80 g/L after treatment with study medication	86
Table 48:	Platelets (x10 ⁹ /L) mean and standard deviation over time by treatment	87

NDA: 20-287/S-10

Page 7

Table 49: Braunwald's classification system for unstable angina '

91

LIST OF FIGURES

<i>Figure 1: RISC trial results '.....</i>	<i>10</i>
<i>Figure 2: Cumulative probability of death and/or MI through Day 40</i>	<i>41</i>

APPEARS THIS WAY ON ORIGINAL

ACRONYMS and ABBREVIATIONS

AE	Adverse event
AMI	Acute myocardial infarction
ASA	Aspirin
aXa	Anti activated factor X
b.i.d.	Twice a day
CABG	Coronary artery bypass grafting
CK	Creatinine kinase
CK-MB	Creatinine kinase, MB band
CMH	Cochran-Mantel-Haenszel
GCP	Good clinical practice
GCP	Good clinical practice
GI	Gastrointestinal
IRB	Institutional review board
ITT	Intention to treat
IU	International units
LMWH	Low molecular weight heparin
LVT	Left ventricular thrombus
MI	Myocardial infarction
mV	Millivolt
p.o.	By mouth
PP	Per protocol
PTCA	Percutaneous transluminal coronary artery angioplasty
PTT	Partial thromboplastin time
q.d.	Every day
s.c.	Subcutaneously
s.d.	Standard deviation
SK	Streptokinase
t.i.d.	Three times a day
UFH	Unfractionated heparin

1. MATERIAL UTILIZED IN REVIEW

1.1 Materials from NDA/IND

A supplemental application, S-010, to NDA 20,287, consisting of 86 volumes was reviewed.

1.2 Related Review, Consults

The medical officer's reviews of IND [REDACTED] NDA 20-287, and NDA 20-287/S-008 and the statistician's review of the current submission were reviewed.

2. BACKGROUND

2.1 Indication

The sponsor has submitted two different indications. The indication stated on form FDA 356h is "Unstable angina and non-Q-wave myocardial infarction." However, the proposed labeling states that "Fragmin® is indicated for the treatment of unstable angina and non-Q-wave myocardial infarction for the prevention of ischemic complications in patients on concomitant aspirin."

2.2 Rationale

2.2.1 Background for Treatment of Unstable Coronary Artery Disease


The sponsor cites two background studies, The RISC trial, and Thérroux's Canadian study.

2.2.1.1 RISC trial¹

The RISK trial enrolled 796 men with unstable coronary artery disease (unstable angina or non-Q-wave myocardial infarction) into a double-blind placebo-controlled study. They were treated with oral aspirin (75 mg/day for a year) and/or 5 days of intermittent intravenous heparin (10000 U iv every 6 hours for 24 hours, then 7500 U every 6 hours for four days without titration to PTT). The risk of MI and deaths was reduced by aspirin. Heparin had no

significant influence on event rate, although the group treated with aspirin and heparin had the lowest number of events during the initial 5 days.

Figure 1: RISC trial results ¹



Aspirin significantly reduced MI and death. Heparin had no significant effect. The sponsor notes that by day five heparin plus aspirin had a significant effect but that aspirin alone did not. However, it was also true at day five that placebo/aspirin was not significantly different from heparin/aspirin.

2.2.1.2 Thérroux et. al., the Canadian study²

Patients (479) were randomized to a placebo-controlled, short-term study comparing the effectiveness of aspirin, heparin or aspirin/heparin, in the treatment of unstable angina.

Aspirin was given at a higher dose than the RISC study (650 mg initially and then 325 mg bid), and heparin was given as a constant infusion and at a different dose (given as a 5000 unit bolus followed by 1000U/hr titrated to 1.5-2 times control PTT). Patients were studied for a maximum of nine days.

Myocardial infarction, compared to placebo, was decreased significantly in all three groups (aspirin, aspirin/heparin, heparin).

Further analysis of these patients showed that there was a significant "reactivation" of disease in the group treated with heparin alone shortly (a

few days) after cessation of heparin. This did not occur in the aspirin or aspirin/heparin groups.³

2.2.2 Rationale for using Fragmin® to treat unstable coronary artery syndromes

Fragmin® is currently approved in the United States for prophylaxis against deep vein thrombosis in patients undergoing abdominal surgery who are at risk for thromboembolic complications. Fragmin® is approved in other countries for the treatment of acute deep venous thrombosis, prevention of clotting in the extracorporeal circulation during hemodialysis, acute and prolonged thromboprophylaxis in surgery, and treatment of unstable angina or non-Q-wave myocardial infarction.

The sponsor contrasts low molecular weight heparins (LMWHs) to unfractionated heparin (UFH) and states that Fragmin is superior in the following respects:

1. Increased bioavailability and longer plasma half-life allow LMWHs to provide a predictable anticoagulant response when administered at fixed doses once or twice daily.
2. Fragmin® is rapidly and almost completely absorbed from the subcutaneous depot and can be administered without the need for continuous monitoring.
3. Long-term treatment with Fragmin® is well tolerated.
4. Fragmin® affects platelet function to a lesser extent than heparin.
5. Fragmin® releases lipoprotein lipase to a lesser extent than unfractionated heparin and may be preferred in clinical situations in which high plasma lipolytic activity is a disadvantage.

2.2.3 Rationale for Fragmin® dosage, acute phase and chronic phase

The studies cited by the sponsor to support their choice of dosing regimens are summarized in Table 1.

2.2.3.1 Acute phase

The sponsor states that the dosing schedule was based on experience with Fragmin in prophylaxis of ventricular thrombosis after acute myocardial infarction.

Studies by Nesvold ⁵ and others used doses of 150 IU/k.g. twice daily, while Scala et. al ⁴ used 120 IU./k.g.

The FRISC trial initially started with a dose of 150 IU/k.g. / 12 hours.

Because of significant bleeding, the trial was halted after 116 patients had been treated and the randomization code for 10 patients was broken.

The trial was then restarted at a dose of 120 IU/k.g. /12 hours.

2.2.3.2 Chronic phase

The dosage chosen for the chronic phase was based on the use of Fragmin in the long-term prophylaxis of thromboembolism after high-risk surgery.

2.3 Administrative History

A new Drug Application for Fragmin® was submitted August 6, 1992, resubmitted December 22, 1992, and finally approved on December 22, 1994, for the following indication at a dose of 2500 IU/s.c. q.d.:

"The prophylaxis of deep venous thrombosis, which may lead to pulmonary embolism, in patients undergoing abdominal surgery who are at risk of thromboembolic complications. Patients at risk include patients who are over 40 years of age, obese, undergoing surgery under general anesthesia lasting longer than 30 minutes or who have additional risk factors such as malignancy or a history of deep vein thrombosis or pulmonary embolism."

Supplement 003, submitted July 7, 1995, was approved March 18, 1996, and provided for the following:

"a 5000 IU dose for the prophylaxis against deep venous thrombosis, which may lead to pulmonary embolism, inpatients undergoing abdominal surgery associated with a high risk of thromboembolic complications, such as malignancy disorder."

Table 1: The studies that the sponsor cites to support their dosing regimens

Study	G	Type of study	Patients				Fragmin® dose and other treatments		Endpoints	Results	Safety
			#	Total Rand om ized Control	Age (mean or median (range))	Type					
Studies cited in support of the acute phase of the study.											
Scala ^a	U	Open label, randomized, heparin (continuous infusion, PTT 1.5-2.5 times control).	39	13/12 30/9		AMI of less than 48h	120 IU/kg b.i.d. a.c. for 7 days		Occurrence of DVT, left ventricular thrombus.	No difference in DVT or thrombus (none in either group). Study too small to draw conclusions. No statistical comparison done.	7 day exposure One patient in Fragin® group ha moderate GI bleed. 1 patient in heparin group had acut anemia without externa bleeding. 3 in each group died of cardiac arrest.
Nesvold ^b	N	Open, non-randomized, dose-finding study.	72	NA 61/11	66 38-75	AMI	Multiple regimens. 240-360 IU/kg/day a.c. bid or tid for 6-10 days some in combination with SK and/or ASA		1 ¹ Define a Fragin® dosage in patients with AMI aiming at anti-Xa levels of 0.6-1.0 IU/ml 2 ² The frequency of left ventricular thrombus as defined by echocardiogram	300 U/kg/day of Fragin®, given bid or tid, thought to be safe with respect to bleeding. Lower incidence of LV thrombus compared to historical controls. No statistical analysis done	6-10 day exposure 300 U/kg/day of Fragin®, given bi or tid, thought to be safe wit respect to bleeding. 4 minor bleeds (all in Fragin® an or SK/ASA group)
FRAMI STUDY Dale ^c	U	Randomized, double-blind, placebo-controlled, parallel-group, multi-center	776	338/338 569/207	63±12 s.d. NA	AMI	Fragmin® 150 IU/bid a.c. every 12 h for 10 days Some with SK Warfarin or ASA		1 ¹ Incidence of LVT 2 ² Incidence of reinfarction, or cardio-cerebrovascular mortality, safety.	No significant differences	Major bleeds higher in Fragin® group 2.8% vs. 0.3% (p 0.004). Minor bleeds also higher in Fragin® group 13.6% vs. 1.8% p 0.001
Nilsen ^d	U	Prospective, active comparator, randomized, open study.	100	36/36 74/22	64±11 s.d. NA	AMI	150 IU or 100 IU /kg a.c. vs. Heparin 12,500 bid a.c. for 7 days All patients got ASA 160 p.o. q.d. and SK 1.5 mill IU over 1 hour		1 ¹ Safety 2 ² Coagulation, incidence of reinfarction death	No significant differences	Significant bleeding in the 150 IU Group. Dose changed to 100 IU ml study.
Studies cited in support of the chronic phase of the study											

¹ Good Clinical Practices: N=no, Y=yes, U=unknown.

Study	G	Type of study	Patients			Fragmin® dose and other treatments	Endpoints	Results	Safety
			#	Total Random # / total	Age (mean or median (range))	Type			
Harenberg	U	Prospective, no controls	70	NA NA	56 25-80	Indication for prophylaxis from thromboembolic event and a history of treatment with oral anticoagulant or heparin who had had problems	Observational study	5 thromboembolic events	31-month exposure with over 4500 of the subjects dropped out by and only 2 patients still in study at month 31. No fatal or severe bleeding. Nin episodes of minor bleeding

Table Constructed by Medical Officer

APPEARS THIS WAY ON ORIGINAL

2.4 Foreign experience

According to the sponsor, Dalteparin is marketed in 48 countries world-wide for use in thromboprophylaxis during hemodialysis, general and orthopedic surgery, and in disseminated intravascular coagulation and is approved for use in unstable coronary artery syndromes in Australia, Austria, Cyprus, Denmark, Finland, The Netherlands, New Zealand, Norway, South Africa, Sweden and the United Kingdom (Page 8/29/311-314).

2.5 Current FDA approved use in the United States

Fragmin is currently used for the prophylaxis against deep venous thrombosis, which may lead to pulmonary embolism, in patients undergoing abdominal surgery and in patients undergoing hip replacement. The current dosing labeling is as follows.

2.5.1 Abdominal Surgery

In patients undergoing abdominal surgery with a risk of thromboembolic complications, the recommended dose of FRAGMIN Injection is 2500 IU administered by subcutaneous (s.c.) injection once daily, starting 1 to 2 hours prior to surgery and repeated once daily for 5 to 10 days postoperatively. In patients undergoing abdominal surgery associated with a high risk of thromboembolic complications, such as malignant disorder, the recommended dose of FRAGMIN is 5000 IU s.c. the evening before surgery, then once daily for 5 to 10 days postoperatively. Alternatively, in patients with malignancy, 2500 IU of FRAGMIN can be administered s.c. 1 to 2 hours before surgery followed by 2500 IU s.c. 12 hours later, and then 5000 IU once daily for 5 to 10 days postoperatively.

2.5.2 Hip Replacement Surgery

In patients undergoing hip replacement surgery, the recommended first dose of FRAGMIN is 2500 IU administered by s.c. injection within 2 hours before surgery and the second dose of 2500 IU s.c. in the evening of the day of surgery (at least 6 hours after the first dose). If surgery is performed in the evening, omit the second dose on the day of surgery. Starting on the first postoperative day, the recommended dose of FRAGMIN is 5000 IU administered by s.c. injection once daily. Alternatively, 5000 IU of FRAGMIN can be administered the evening before surgery, followed by 5000 IU once daily, starting in the evening of the day of surgery. Up to 14 days of

treatment was well tolerated in controlled clinical trials, where the average duration of treatment was 5 to 10 days postoperatively.

3. REVIEW OF INDIVIDUAL STUDIES

3.1 Overview of studies submitted

The studies included in this submission are summarized in Table 2.

3.1.1 FRISC

FRISC, the first of two pivotal studies in this submission, was a prospective, randomized, double blind, placebo-controlled, parallel group, multi-center study in patients with unstable coronary artery syndromes (unstable angina or non-Q-wave MI).

Phase I (day 1-6) and Phase II (day 6-45) both compared Fragmin/ASA treatment versus placebo/ASA.

The primary endpoint of the study was death and/or myocardial infarction during the first 6 days of treatment.

3.1.2 FRIC

FRIC, the second of two pivotal studies in this submission, was a prospective, randomized, controlled parallel group multi-center, two-phase study, in patients with unstable coronary artery syndromes (unstable angina or non-Q-wave MI).

Phase I (day 1-6) was open label and Phase II (day 6-45) was double-blinded.

Phase I compared Fragmin/ASA to heparin/ASA. Phase II compared Fragmin/ASA to placebo/ASA.

The primary endpoint was the incidence of death, myocardial infarction and/or recurrence of angina during Phase II.

3.1.3 FRISC II

FRISC II is an ongoing prospective, randomized, parallel-arm, multi-center, two-phase trial, in patients with unstable coronary artery syndromes (unstable angina or non-Q-wave MI).

Phase I (day 1 to day 5-7) is open-label Fragmin/ASA for all patients. Phase II (day 6-90) is a double-blind comparison of Fragmin/ASA and placebo/ASA.

The primary endpoints are death or myocardial infarction after 3 and 6 months.

3.1.4 FRAMI

FRAMI was a prospective, placebo-controlled, randomized, double blind, parallel arm study, in patients with their first anterior-wall myocardial infarction.

Patients were treated with Fragmin/ASA or placebo/ASA for 10 days.

90% of the patients also received streptokinase.

The primary endpoints were left-ventricular thrombus and arterial emboli.

3.1.5 Other studies

TRN91-111 was a prospective, open-label, randomized pilot study in patients with acute myocardial infarctions who were also treated with streptokinase.

CTN 88-009 was an uncontrolled dose-finding study.

TRN 88-084 was an open trial comparing Fragmin and streptokinase to streptokinase alone in patients with acute myocardial infarctions.

BIOMACS II was a randomized, double blind, placebo-controlled, parallel-group, multi-center, pilot study comparing Fragmin to placebo before and after streptokinase in patients with acute myocardial infarctions.